Efficacy of human immunoglobulin in adjuvant treatment of neonatal pneumonia and its effect on inflammatory factors and immune function

Investigate the efficacy of human immunoglobulin in the adjuvant treatment of neonatal pneumonia. A total of 116 children with neonatal pneumonia were treated in our hospital from March 2022 to March 2024 were selected and they were randomly divided into control group(n=58,receiving conventional treatment)and observation group(n=58,receiving conventional treatment+human immunoglobulin treatment), compar the treatment efficacy,immune function indicators and inflammatory factor levels before and after intervention, and the occurrence of adverse reactions. The total effective rate in the observation group was higher than that in the control group (P<0.05); compared with the control group, the level of inflammatory factors in the observation group was lower after treatment (P<0.05); after treatment, compared with the control group, the level of immune function indicators in the observation group was higher (P<0.05); There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05 ). Human immunoglobulin adjuvant treatment of neonatal pneumonia can reduce the level of inflammatory factors and improve the immune function in children, the treatment efficacy is significant and safe.